Ingevity Corporation (NYSE:NGVT) Given Average Rating of “Hold” by Brokerages

by · The Cerbat Gem

Shares of Ingevity Corporation (NYSE:NGVT – Get Free Report) have been assigned a consensus rating of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $80.00.

NGVT has been the subject of several recent analyst reports. Wall Street Zen cut Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Weiss Ratings upgraded shares of Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, July 31st.

Check Out Our Latest Analysis on Ingevity

Ingevity Stock Performance

Shares of NGVT opened at $68.17 on Monday. Ingevity has a 1 year low of $45.85 and a 1 year high of $79.29. The company’s 50 day simple moving average is $72.18 and its 200 day simple moving average is $71.34. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of 46.38 and a beta of 1.17. The company has a debt-to-equity ratio of 22.52, a quick ratio of 1.15 and a current ratio of 1.61.

Ingevity (NYSE:NGVT – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.41. The company had revenue of $314.10 million for the quarter, compared to analyst estimates of $312.20 million. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, sell-side analysts predict that Ingevity will post 5.4 EPS for the current year.

Insider Activity at Ingevity

In related news, CEO David Li sold 5,000 shares of Ingevity stock in a transaction on Monday, August 17th. The shares were sold at an average price of $75.83, for a total transaction of $379,150.00. Following the transaction, the chief executive officer owned 120,636 shares in the company, valued at approximately $9,147,827.88. The trade was a 3.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ryan Fisher sold 2,709 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $73.72, for a total value of $199,707.48. Following the completion of the sale, the senior vice president directly owned 15,722 shares of the company’s stock, valued at $1,159,025.84. The trade was a 14.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 17,801 shares of company stock worth $1,347,481 in the last 90 days. 0.88% of the stock is currently owned by insiders.

Institutional Trading of Ingevity

Several institutional investors have recently added to or reduced their stakes in NGVT. Assetmark Inc. lifted its stake in Ingevity by 9.6% during the first quarter. Assetmark Inc. now owns 1,584 shares of the company’s stock worth $113,000 after purchasing an additional 139 shares during the last quarter. Legato Capital Management LLC raised its holdings in shares of Ingevity by 11.6% during the fourth quarter. Legato Capital Management LLC now owns 4,339 shares of the company’s stock worth $257,000 after purchasing an additional 451 shares during the period. ProShare Advisors LLC lifted its position in shares of Ingevity by 6.0% in the 4th quarter. ProShare Advisors LLC now owns 8,072 shares of the company’s stock worth $478,000 after buying an additional 460 shares during the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of Ingevity in the 2nd quarter valued at about $37,000. Finally, Evolve Private Wealth LLC grew its position in shares of Ingevity by 10.2% during the 1st quarter. Evolve Private Wealth LLC now owns 5,946 shares of the company’s stock valued at $424,000 after buying an additional 549 shares during the last quarter. 91.59% of the stock is owned by institutional investors and hedge funds.

About Ingevity

(Get Free Report)

Ingevity Corporation (NYSE: NGVT) is a specialty chemicals and materials company that develops products designed to improve performance, sustainability and resource efficiency across a range of industrial and consumer applications. Its businesses serve automotive, infrastructure, industrial, agricultural and other end markets.

The company’s portfolio includes activated carbon products used in vehicle evaporative-emissions control systems, industrial air and water purification, and other filtration applications.

Recommended Stories